Clinical trialEPhase 1Recruiting
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
A Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of ES502 Injection in Patients With Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 18 May 2026
- Expected end
- June 2029
- Enrollment
- 24 participants
- Sites
- 1
- Primary outcomes
- To evaluate the safety and tolerability of ES502 in subjects with advanced solid tumors; To determine the maximum tolerated dose (MTD)
- Sponsor
- Other
- Results posted
- No
- Last update
- 16 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
ESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).
Detailed description public domain (ClinicalTrials.gov)
The study will adopt the standard "3+3" design., with a first-in-human (FIH) dose of 20 μg administered once every four weeks (Q4W). Subsequent dosing frequency will be adjusted based on pharmacodynamics and pharmacokinetics data. The primary objectives of this study are to evaluate the safety and tolerability of ES502 and to determine its maximum tolerated dose (MTD). The secondary objectives are to evaluate its antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD).